offline
Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
Allergan plc’s AGN second-quarter adjusted earnings came in at $4.38 per share, which beat the Zacks Consensus Estimate of $4.34 and came within the guided range of $4.20 and $4.40. Earnings however declined 0.9% year over year due to lower operating profits.
Revenues came in at $4.09 billion, which exceeded the Zacks Consensus Estimate of $3.94 billion as well as the guidance of $3.88 billion to $4.03 billion. Revenues fell 0.8% from the year-ago period primarily due to currency headwinds. Excluding the impact of currency, total revenues rose 1.2% as higher sales of key products like Botox (cosmetic and therapeutics), Juvéderm collection of fillers, Vraylar, Ozurdex, and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others in 2018.
...
https://finance.yahoo.com/news/allergan-...02803.html
![[Bild: AGNc1dl1425.png]](https://finviz.com/publish/080619/AGNc1dl1425.png)
Allergan plc’s AGN second-quarter adjusted earnings came in at $4.38 per share, which beat the Zacks Consensus Estimate of $4.34 and came within the guided range of $4.20 and $4.40. Earnings however declined 0.9% year over year due to lower operating profits.
Revenues came in at $4.09 billion, which exceeded the Zacks Consensus Estimate of $3.94 billion as well as the guidance of $3.88 billion to $4.03 billion. Revenues fell 0.8% from the year-ago period primarily due to currency headwinds. Excluding the impact of currency, total revenues rose 1.2% as higher sales of key products like Botox (cosmetic and therapeutics), Juvéderm collection of fillers, Vraylar, Ozurdex, and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others in 2018.
...
https://finance.yahoo.com/news/allergan-...02803.html
__________________
